Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $40
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and lowers the price target from $42 to $40.
Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and lowers the price target from $42 to $40.